Cemiplimab vs Penpulimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Cemiplimab
Marketed by Regeneron Pharmaceuticals and partners
NCT03088540 · Phase 3 · completed
This was a large, randomized, actively-controlled trial with two hard clinical endpoints, survival and progression-free survival, both of which showed a statistically significant benefit for cemiplimab (median overall survival 23.4 vs 13.7 months; progression-free survival assessed by an independent, blinded reviewer). However, patients and treating doctors knew which treatment was being given, since the study was not blinded, which is a real limitation despite the otherwise strong design and the clear-cut result.
Next expected readout: December 2026 · NCT06623656 (registry estimate)
Reported efficacy
Overall Survival (OS) (Up to 94 months); Progression-free Survival (PFS) Per Blinded IRC (Up to 94 months): Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2) (met)
Result source: NCT03088540
Penpulimab
Marketed by Akeso and partners
NCT03866993 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled Phase 3 trial in 350 patients with advanced squamous non-small-cell lung cancer, all of whom also received paclitaxel and carboplatin. An independent radiology committee assessed progression-free survival in two primary populations: all randomized patients and the PD-L1-positive subgroup. Penpulimab improved progression-free survival in both populations (median 7.6 vs 4.2 months overall and 8.1 vs 4.2 months in PD-L1-positive patients, both p<0.0001), so the trial met its primary endpoint. The figures come from the peer-reviewed Lancet Respiratory Medicine paper.
Reported efficacy
Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1 (Up to approximately 2 years); PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1 (Up to approximately 2 years): Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. (met)
Result source: NCT03866993
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cemiplimab | Penpulimab |
|---|---|---|
| PFS, median | 6.3 vs 5.3vs ChemotherapyNCT030885403 other results
| 8.6 vs 4.2a+4.4 vs placeboNCT03866993 |
| OS, median | 21.1 vs 12.9+8.2 vs placeboNCT034096143 other results
| —Not posted · NCT03866993 |
| ORR | 43.6% vs 22.1%+21.5 vs placeboNCT034096143 other results
| —Not posted · NCT03866993 |
| Duration of response, median | 16.4 vs 7.3+9.1 vs placeboNCT034096143 other results
| —Not posted · NCT03866993 |
PFS, median
- Cemiplimab
- 6.3 vs 5.3vs ChemotherapyNCT03088540
3 other results
- 8.2 vs 5.5 NCT03409614
- 6.5 vs 6.4 NCT03409614
- 6.4 vs 6.4 NCT03409614
- Penpulimab
- 8.6 vs 4.2a+4.4 vs placeboNCT03866993
OS, median
- Cemiplimab
- 21.1 vs 12.9+8.2 vs placeboNCT03409614
3 other results
- 23.4 vs 13.7 NCT03088540
- 15.9 vs 13.9 NCT03409614
- 20.1 vs 13.9 NCT03409614
- Penpulimab
- —Not posted · NCT03866993
ORR
- Cemiplimab
- 43.6% vs 22.1%+21.5 vs placeboNCT03409614
3 other results
- 42.3% vs 21.4% NCT03088540
- 40.7% vs 28.3% NCT03409614
- 36.7% vs 28.3% NCT03409614
- Penpulimab
- —Not posted · NCT03866993
Duration of response, median
- Cemiplimab
- 16.4 vs 7.3+9.1 vs placeboNCT03409614
3 other results
- 24.1 vs 5.9 NCT03088540
- 7.8 vs 6.2 NCT03409614
- 15.9 vs 6.2 NCT03409614
- Penpulimab
- —Not posted · NCT03866993
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Cemiplimab: 4 of 4 rows · Penpulimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cemiplimab | Penpulimab |
|---|---|---|
| Dropout rate | 79%Cemiplimaba NCT03088540 · Phase 3 show 10 more results—Extended Treatment: Cemiplimab + C NCT03088540 · Phase 3 · combination 90.7%Part 1: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 91.7%Part 1: Cemiplimab+AbbrevChemo+Ipi NCT03409614 · Phase 3 · combination 90.1%Part 2: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 0%30 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 0%10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | — |
| Discontinued due to AEs | 0.3%Cemiplimaba NCT03088540 · Phase 3 show 10 more results—Extended Treatment: Cemiplimab + C NCT03088540 · Phase 3 · combination 0%Part 1: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 0%Part 1: Cemiplimab+AbbrevChemo+Ipi NCT03409614 · Phase 3 · combination 0.3%Part 2: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination —30 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination —10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | — |
| Serious AEs | 36.8%Cemiplimaba NCT03088540 · Phase 3 show 10 more results27.1%Extended Treatment: Cemiplimab + C NCT03088540 · Phase 3 · combination 35.2%Part 1: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 35.8%Part 1: Cemiplimab+AbbrevChemo+Ipi NCT03409614 · Phase 3 · combination 30.4%Part 2: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 33.3%30 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 40%20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 23.8%20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 11.1%10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 25%3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 60%1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | — |
| Most frequent reported AEs | show 10 more resultsanaemia 48.1% (placebo 39.9%) neutropenia 28.7% (placebo 12.4%) alopecia 27.8% (placebo 43.8%) NCT03409614 · Phase 3 · combination anaemia 33.9% (placebo 39.9%) nausea 28.4% (placebo 16.3%) fatigue 21.1% (placebo 8.5%) NCT03409614 · Phase 3 · combination anaemia 44.2% (placebo 39.9%) alopecia 37.5% (placebo 43.8%) nausea 25.3% (placebo 16.3%) NCT03409614 · Phase 3 · combination 30 mg/kg infusion related reaction 66.7% anaemia 33.3% abdominal pain 26.7% NCT05259696 · Phase 1/2 · registry result, not featured evidence 20 mg/kg infusion related reaction 66.7% anaemia 40% constipation 26.7% NCT05259696 · Phase 1/2 · registry result, not featured evidence 20 mg/kg in combination with cemiplimab infusion related reaction 42.9% cough 33.3% fatigue 33.3% NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 10 mg/kg infusion related reaction 55.6% fatigue 33.3% dehydration 22.2% NCT05259696 · Phase 1/2 · registry result, not featured evidence 3 mg/kg abdominal pain 25% arthralgia 25% back pain 25% NCT05259696 · Phase 1/2 · registry result, not featured evidence 1 mg/kg abdominal pain 60% nausea 60% vomiting 40% NCT05259696 · Phase 1/2 · registry result, not featured evidence | — |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cemiplimab
show 3 more results
show 3 more results
show 3 more results
show 2 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
+ 39 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemiplimab's landscape · Penpulimab's landscape